Mutational Landscape and Treatment Response in Extensive-Stage Small-Cell Lung Cancer: A Single-Center Real-World Analysis
Current Oncology · 29.04.2026 · 33 (5) · 256
DOI: 10.3390/curroncol33050256 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 29.04.2026. Verfasst von Meizeng Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Mutation, Small Cell Lung Carcinoma. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objectives
Small-cell lung cancer (SCLC) is an aggressive malignancy often diagnosed at the extensive stage (ES-SCLC). While chemoimmunotherapy (CIT) has emerged as a first-line option, SCLC’s “cold” immune profile limits broad efficacy. This study evaluates the real-world clinical efficacy of CIT versus chemotherapy (CT) alone and analyzes the association between gene mutation characteristics and clinical indicators.
Methods
We retrospectively analyzed 170 patients with ES-SCLC treated at a single center between January 2020 and January 2024. Patients were categorized by first-line treatment (CIT vs. CT). Subgroup analyses were conducted to evaluate treatment response. Genomic profiling was integrated for a subset of patients to identify associations between mutation signatures and clinicopathological factors.
Results
Of the 115 patients (67.6%) who received CIT and 55 (32.4%) who received CT, the CIT group achieved a significantly higher objective response rate (76.5% vs. 56.4%). Median progression-free survival was numerically but not significantly longer in the CIT group (6.0 vs. 5.8 months). Adrenal metastasis was identified as an independent adverse prognostic factor. Genomic analysis revealed site-specific correlations: MYC mutations with pleural metastasis, NTRK3 with brain metastasis, ALK with adrenal metastasis, and NTRK1 with intrapulmonary metastasis. Additionally, smokers showed higher mutation frequencies in SMAD4 and PIK3CA.
Conclusions
CIT significantly improves initial response rates in ES-SCLC compared to CT alone. Baseline adrenal metastasis serves as a poor prognostic indicator. Distinct genomic mutation signatures are associated with clinical characteristics, suggesting potential pathways for personalized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, M., Guo, L., Zhao, R., Chen, S., Ma, S., Xiang, C., & Han, Y. (2026). Mutational Landscape and Treatment Response in Extensive-Stage Small-Cell Lung Cancer: A Single-Center Real-World Analysis. Current Oncology, 33(5), 256. https://doi.org/10.3390/curroncol33050256
Vancouver
Li M, Guo L, Zhao R, Chen S, Ma S, Xiang C, et al. Mutational Landscape and Treatment Response in Extensive-Stage Small-Cell Lung Cancer: A Single-Center Real-World Analysis. Current Oncology. 2026;33(5):256. doi:10.3390/curroncol33050256
BibTeX
@article{Li2026,
author = {Li, Meizeng and Guo, Lianying and Zhao, Ruiying and Chen, Shengnan and Ma, Shengji and Xiang, Chan and Han, Yuchen},
title = {Mutational Landscape and Treatment Response in Extensive-Stage Small-Cell Lung Cancer: A Single-Center Real-World Analysis},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {5},
pages = {256},
doi = {10.3390/curroncol33050256}
}
EUVIMED